Advertisement

Supportive Care in Cancer

, Volume 23, Issue 2, pp 525–545 | Cite as

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review

  • Alena M. Pfeil
  • Kim Allcott
  • Ruth Pettengell
  • Gunter von Minckwitz
  • Matthias Schwenkglenks
  • Zsolt Szabo
Review Article

Abstract

Purpose

Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimulating factors (G-CSFs) have recently been developed. We systematically reviewed the efficacy, effectiveness and safety of neutropenia prophylaxis with long-acting G-CSFs in cancer patients receiving chemotherapy.

Methods

We performed a systematic literature search of the MEDLINE, EMBASE and Cochrane Library databases, and abstracts from key congresses. Studies of long-acting G-CSFs for prophylaxis of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) were identified by two independent reviewers. Abstracts and full texts were assessed for final inclusion; risk of bias was evaluated using the Cochrane’s tool. Effectiveness and safety results were extracted according to study type and G-CSF used.

Results

Of the 839 articles identified, 41 articles representing different studies met the eligibility criteria. In five randomised controlled trials, 11 clinical trials and 17 observational studies across several tumour types and chemotherapy regimens, pegfilgrastim was used alone or compared with daily G-CSF, no G-CSF, no upfront pegfilgrastim or placebo. Studies generally reported lower incidence of CIN (4/7 studies), FN (11/14 studies), hospitalisations (9/13 studies), antibiotic use (6/7 studies) and adverse events (2/5 studies) with pegfilgrastim than filgrastim, no upfront pegfilgrastim or no G-CSF. Eight studies evaluated other long-acting G-CSFs; most (5/8) were compared to pegfilgrastim and involved patients with breast cancer receiving docetaxel-based therapy. Efficacy and safety profiles of balugrastim and lipegfilgrastim were comparable to pegfilgrastim in phase 3 studies. Efficacy and safety of other long-acting G-CSFs were mixed.

Conclusions

Pegfilgrastim reduced the incidence of FN and CIN compared with no prophylaxis. Most studies showed better efficacy and effectiveness for pegfilgrastim than filgrastim. Efficacy and safety profiles of lipegfilgrastim and balugrastim were similar to pegfilgrastim.

Keywords

Balugrastim Granulocyte colony-stimulating factor Lipegfilgrastim Neutropenia Pegfilgrastim Systematic review 

Notes

Acknowledgements

We would like to thank Ryan Bishop and Iain Fotheringham from Oxford PharmaGenesis™ Ltd (UK) for providing assistance with designing and conducting the systematic review. Funding for this support was provided by Amgen (Europe) GmbH. We would also like to acknowledge James O’Kelly of Amgen Ltd for coordinating our research collaboration, for doing the second risk of bias assessment and for his valuable feedback on the manuscript.

Authors’ contributions

All authors were involved in the design of the study. KA was responsible for the first draft of the protocol, which was critically reviewed, further developed and approved by all authors. KA performed the literature search, and collected and extracted the data. AMP was responsible for the risk of bias assessment and the first draft of the manuscript. KA and AMP were responsible for the second draft. All authors contributed to data interpretation, critically reviewed all manuscript versions and approved the final version.

Conflicts of interest

AMP’s institution of employment receives unrestricted scientific/educational grants from Amgen. KA is an employee of Oxford PharmaGenesis™ Ltd, which has received project funding from Amgen. RP received honoraria from Amgen and Roche. GvM receives research funding from Amgen and Teva and served on an advisory board for Amgen. MS’s institution of employment receives unrestricted scientific/educational grants from Amgen and he has served on advisory boards for Amgen. ZS is an employee of Amgen and owns stock and stock options in the company.

Supplementary material

520_2014_2457_MOESM1_ESM.docx (141 kb)
ESM 1 (DOCX 141 kb)

References

  1. 1.
    Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol: Off J Eur Soc Med Oncol ESMO 21(Suppl 5):v248–v251. doi: 10.1093/annonc/mdq195 CrossRefGoogle Scholar
  2. 2.
    Dale DC (2009) Advances in the treatment of neutropenia. Curr Opin Support Palliat Care 3(3):207–212. doi: 10.1097/SPC.0b013e32832ea6ae PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Rossi L, Tomao F, Lo Russo G, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S (2013) Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Ther Clin Risk Manag 9:457–462. doi: 10.2147/TCRM.S48387 PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer Netw: JNCCN 7(1):99–108PubMedGoogle Scholar
  5. 5.
    Saloustros E, Tryfonidis K, Georgoulias V (2011) Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opin Pharmacother 12(6):851–863. doi: 10.1517/14656566.2011.541155 PubMedCrossRefGoogle Scholar
  6. 6.
    Curran MP, Goa KL (2002) Pegfilgrastim. Drugs 62(8):1207–1213, discussion 1214–1205PubMedCrossRefGoogle Scholar
  7. 7.
    Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (Oxford, England: 1990) 47(1):8–32. doi: 10.1016/j.ejca.2010.10.013 CrossRefGoogle Scholar
  8. 8.
    Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M (2011) Myeloid growth factors. J Natl Compr Cancer Netw: JNCCN 9(8):914–932PubMedGoogle Scholar
  9. 9.
    Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol: Off J Am Soc Clin Oncol 24(19):3187–3205. doi: 10.1200/JCO.2006.06.4451 CrossRefGoogle Scholar
  10. 10.
    Yang BB, Savin MA, Green M (2012) Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. Chemotherapy 58(5):387–398. doi: 10.1159/000345626 PubMedCrossRefGoogle Scholar
  11. 11.
    European Medicines Agency (2013) European public assessment report for Lonquex. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002556/WC500148383.pdf. Accessed 4 February 2014
  12. 12.
    Hoggatt J, Pelus LM (2013) New G-CSF agonists for neutropenia therapy. Expert Opin Investig Drugs. doi: 10.1517/13543784.2013.838558 PubMedGoogle Scholar
  13. 13.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34. doi: 10.1016/j.jclinepi.2009.06.006 PubMedCrossRefGoogle Scholar
  14. 14.
    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. doi: 10.1136/bmj.d5928 PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters LM, Santaguida PL, Shamliyan T, Singh K, Tsertsvadze A, Treadwell JR (2012) Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews AHRQ Publication No. 12-EHC047-EFGoogle Scholar
  16. 16.
    Bondarenko I, Gladkov OA, Elaesser R, Buchner A, Bias P (2013) Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 13(1):386. doi: 10.1186/1471-2407-13-386 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Almenar Cubells D, Bosch Roig C, Jimenez Orozco E, Alvarez R, Cuervo JM, Diaz Fernandez N, Sanchez Heras AB, Galan Brotons A, Giner Marco V, Codes MDVM (2013) Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. Eur J Cancer Care 22(3):400–412. doi: 10.1111/ecc.12043 CrossRefGoogle Scholar
  18. 18.
    Volovat C, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Bias P, Adar L, Avisar N (2013) Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. Clin Breast Cancer. doi: 10.1016/j.clbc.2013.10.001 PubMedGoogle Scholar
  19. 19.
    Gladkov O, Bondarenko I, Elsaesser R, Buchner A, Bias P (2012) Absolute neutrophil counts in a study of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 23:abstr 1548PDGoogle Scholar
  20. 20.
    Almenar-Cubells D, Roig CB, Jimenez E, M AC, Cuervo JM, Diaz N, Sanchez AB, Galan A, Giner V, Codes M (2011) Daily G-CSFs versus pegfilgrastim (PEG) in cancer patients (pts) undergoing chemotherapy (CT): a multivariate analysis from clinical practice. J Clin Oncol: Off J Am Soc Clin Oncol 29 (15 suppl. 1):(suppl; abstr e19526)Google Scholar
  21. 21.
    Volovat CD, Gladkov O, Bondarenko IN, Barajas-Figueroa LJ, Buchner A, Avisar N, Bianchi S (2012) Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 30:(suppl; abstr 9125)Google Scholar
  22. 22.
    Gladkov OA, Volovat C, Bondarenko I, Elaesser R, Buchner A, Bias P, Mueller U (2012) Efficacy and safety of lipegfilgrastim in patients with lung cancer who are receiving chemotherapy. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 20(Suppl 1):S243Google Scholar
  23. 23.
    Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol: Off J Am Soc Clin Oncol 23(6):1178–1184. doi: 10.1200/JCO.2005.09.102 CrossRefGoogle Scholar
  24. 24.
    Decaestecker J, Cesas A, Hotko Y, Abella E, Mo M, Rogowski W (2013) Regional differences in reported febrile neutropenia (FN), adverse events (AES), and serious AES (SAES) in a multinational phase 3 trial. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer TBC:TBCGoogle Scholar
  25. 25.
    Pinter T, Abella S, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva GP, Novotny J, O’Reilly S, Salek T, Mo MF, Choi LMR, Blanke CD (2013) Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). J Clin Oncol: Off J Am Soc Clin Oncol 30 (suppl 34; abstr LBA445)Google Scholar
  26. 26.
    Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I (2010) A randomized, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 9(2):95–101. doi: 10.3816/CCC.2010.n.013 PubMedCrossRefGoogle Scholar
  27. 27.
    Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 20(3):727–731CrossRefGoogle Scholar
  28. 28.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study G (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol: Off J Eur Soc Med Oncol ESMO 14(1):29–35CrossRefGoogle Scholar
  29. 29.
    Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP (2005) Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 23(33):8340–8347. doi: 10.1200/JCO.2005.02.8621 CrossRefGoogle Scholar
  30. 30.
    Loibl S, Mueller V, Von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V (2011) Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer 19:1789–1795. doi: 10.1007/s00520-010-1020-9 PubMedCrossRefGoogle Scholar
  31. 31.
    Pippen J, Paul D, Vukelja S, Clawson A, Iglesias J (2011) Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Res Treat 130:825–831. doi: 10.1007/s10549-011-1678-9 CrossRefGoogle Scholar
  32. 32.
    Yardley DA, Zubkus J, Daniel B, Inhorn R, Lane CM, Vazquez ER, Naot Y, Burris HA, Hainsworth JD 3rd (2010) A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clin Breast Cancer 10(5):367–372. doi: 10.3816/CBC.2010.n.048 PubMedCrossRefGoogle Scholar
  33. 33.
    Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR (2008) Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol 3:1159–1165PubMedCrossRefGoogle Scholar
  34. 34.
    Toppo L, Tomasello G, Liguigli W, Ratti M, Poli R, Negri F, Curti A, Vismarra M, Maltese M, Delfrate R, Donini M, Colombi C, Brighenti M, Panni S, Perrucci B, Lazzarelli S, Passalacqua R (2013) Efficacy and safety of dose-dense modified TCF regimen (TCF-dd) in metastatic or locally advanced gastroesophageal cancer (GEC). J Clin Oncol: Off J Am Soc Clin Oncol 31:(suppl; abstr 4112)Google Scholar
  35. 35.
    Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L (2007) Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 12(4):484–494. doi: 10.1634/theoncologist.12-4-484 PubMedCrossRefGoogle Scholar
  36. 36.
    Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416–1424. doi: 10.1634/theoncologist.12-12-1416 PubMedCrossRefGoogle Scholar
  37. 37.
    von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M, German Breast G (2008) Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol: Off J Eur Soc Med Oncol ESMO 19(2):292–298CrossRefGoogle Scholar
  38. 38.
    Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R, Sulkes A, Stemmer SM (2011) Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study. Am J Clin Oncol 34(6):619–624. doi: 10.1097/COC.0b013e3181f94716 PubMedCrossRefGoogle Scholar
  39. 39.
    Chan A, Leng XZ, Chiang JY, Tao M, Quek R, Tay K, Lim ST (2011) Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia Pac J Clin Oncol 7:75–81. doi: 10.1111/j.1743-7563.2010.01355.x PubMedCrossRefGoogle Scholar
  40. 40.
    Ng JH, Ang XY, Tan SH, Tao M, Lim ST, Chan A (2011) Breakthrough febrile neutropenia and associated complications in non-Hodgkin’s lymphoma patients receiving pegfilgrastim. Acta Haematol 125:107–114. doi: 10.1159/000321545 PubMedCrossRefGoogle Scholar
  41. 41.
    Hamilton EP, Topping DL, Peppercorn JM, Marcom PK, Kimmick GG, Duff E, Cirrincione CT, Blackwell KL (2013) Clinical impact of febrile neutropenia (FN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 31:(suppl; abstr 1076)Google Scholar
  42. 42.
    Jenkins P, Scaife J, Freeman S (2012) Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol: Off J Eur Soc Med Oncol ESMO 23(7):1766–1771. doi: 10.1093/annonc/mdr493 CrossRefGoogle Scholar
  43. 43.
    Ngamphaiboon N, O’Connor TL, Advani PP, Levine EG, Kossoff EB (2012) Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. Med Oncol 29:1495–1501. doi: 10.1007/s12032-011-0035-5 PubMedCrossRefGoogle Scholar
  44. 44.
    Almenar D, Mayans J, Juan O, Bueno JMG, Lopez JIJ, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain—results of the LEARN Study. Eur J Cancer Care 18:280–286. doi: 10.1111/j.1365-2354.2008.00959.x CrossRefGoogle Scholar
  45. 45.
    Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337–348PubMedGoogle Scholar
  46. 46.
    Jurczak W, Kalinka-Warzocha E, Chmielowska E, Duchnowska R, Wojciechowska-Lampka E, Wieruszewska K (2013) Multicentre, prospective observational study of pegfilgrastim primary prophylaxis (PP) in patients at high risk of febrile neutropenia (FN) in Poland. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer TBC:TBCGoogle Scholar
  47. 47.
    Leung M, Eustaquio J, Kano J, Marr T, Higgins BP, Myers RE, Kim J, Jones G (2012) Pain severity and impairment of activity between pegfilgrastim (P) and fixed-dose filgrastim (F) in women with early-stage breast cancer receiving chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 30 (suppl; abstr e19570)Google Scholar
  48. 48.
    Hershman D, Hurley D, Wong M, Morrison VA, Malin JL (2009) Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ 12(3):203–210. doi: 10.3111/13696990903238603 PubMedCrossRefGoogle Scholar
  49. 49.
    Salar A, Lopez A, Pío Torres J, Lopez MD, Caballero MD, Prieto E, Batlle M, Giraldo P, Blasco A, Benedit P, Garrido T (2009) Incidence of chemotherapy-induced neutropenia in lymphoma patients and use of prophylaxis with granulocyte colony-stimulating factors in clinical practice. Haematologica 94:521, abstr 1315Google Scholar
  50. 50.
    Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13(11). doi: 10.1186/1471-2407-13-11
  51. 51.
    Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS (2009) Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 115(20):4839–4848. doi: 10.1002/cncr.24535 PubMedCrossRefGoogle Scholar
  52. 52.
    Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J (2011) Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 27:79–86. doi: 10.1185/03007995.2010.536527 PubMedCrossRefGoogle Scholar
  53. 53.
    Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31:1069–1081. doi: 10.1016/j.clinthera.2009.05.019 PubMedCrossRefGoogle Scholar
  54. 54.
    Henk HJ, Becker L, Tan H, Yu J, Kavati A, Naeim A, Deeter R, Barron R (2013) Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ 16:160–168. doi: 10.3111/13696998.2012.734885 PubMedCrossRefGoogle Scholar
  55. 55.
    Buchner A, Bias P, Kaufmann M (2011) A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy. J Clin Oncol: Off J Am Soc Clin Oncol 29:(suppl; abstr 9080)Google Scholar
  56. 56.
    Salafet OV, Chernovskaya TV, Sheveleva LP, Khorinko AV, Prokopenko TI, Nechaeva MP, Burdaeva ON, Matrosova MP, Kovalenko NV, Ovchinnikova EG, Koroleva I, Ivanov RA (2013) Efficacy and safety of BCD-017, a novel pegylated filgrastim: results of open-label controlled phase II study in patients with breast cancer receiving myelosuppressive chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 31:(suppl; abstr e20593)Google Scholar
  57. 57.
    Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY, Oberling F, Capdeville R, Newman C, Meresse V, Xu ZX, Platzer E, Van der Auwera P, Maraninchi D (2002) Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol: Off J Am Soc Clin Oncol 20(1):24–36CrossRefGoogle Scholar
  58. 58.
    Schwartzberg LS, Sankar SL, Apt D, Goldstein E, Vetticaden SJ, Chitour K, Gilfoyle D, Kim S, Keiholz U, Possibger K (2009) An open-label, dose-escalating study of Maxy-G34, a novel potent, long-acting Pegylated G-CSF, compared with pegfilgrastim (PF) for the treatment of chemotherapy induced neutropenia (CIN). J Clin Oncol: Off J Am Soc Clin Oncol 27:(suppl; abstr e14500)Google Scholar
  59. 59.
    Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. doi: 10.1186/1471-2407-11-404 PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23(9):2283–2295. doi: 10.1185/030079907X219599 PubMedCrossRefGoogle Scholar
  61. 61.
    Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol: Off J Am Soc Clin Oncol 25(21):3158–3167. doi: 10.1200/JCO.2006.08.8823 CrossRefGoogle Scholar
  62. 62.
    Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol: Off J Eur Soc Med Oncol ESMO 24(10):2475–2484. doi: 10.1093/annonc/mdt226 CrossRefGoogle Scholar
  63. 63.
    Gladkov O, Moiseyenko V, Bondarenko IN, Shparyk JV, Barash S, Herpst JM, Mueller U (2012) A randomized, non-inferiority study of balugrastim and pegfilgrastim in breast cancer patients receiving myelosuppressive therapy. Support Care Cancer 20:S234Google Scholar
  64. 64.
    Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Buchner T, Hiddemann W (2009) Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 113(17):3903–3910. doi: 10.1182/blood-2008-07-162842 PubMedCrossRefGoogle Scholar
  65. 65.
    Noga SJ, Choksi JK, Ding B, Dreiling L, Ozer H (2007) Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. Clin Lymphoma Myeloma 7:413–420. doi: 10.3816/CLM.2007.n.020 PubMedCrossRefGoogle Scholar
  66. 66.
    Rader M, Breyer W, Leudke S, Ding B, Dreiling L, Ozer H (2010) Low rate of neutropenia and related events in patients with breast cancer receiving pegfilgrastim from the first cycle of chemotherapy in community practices. Commun Oncol 7:273–280CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Alena M. Pfeil
    • 1
  • Kim Allcott
    • 2
  • Ruth Pettengell
    • 3
  • Gunter von Minckwitz
    • 4
  • Matthias Schwenkglenks
    • 1
  • Zsolt Szabo
    • 5
  1. 1.Institute of Pharmaceutical MedicineUniversity of BaselBaselSwitzerland
  2. 2.Oxford PharmaGenesis™ LtdOxfordUK
  3. 3.Cellular and Molecular MedicineSt. George’s University of LondonLondonUK
  4. 4.German Breast GroupNeu-Isenburg and University of FrankfurtFrankfurtGermany
  5. 5.Clinical DevelopmentAmgen Europe GmbHZugSwitzerland

Personalised recommendations